所有促性腺激素释放激素激动剂治疗前列腺癌等效吗?一项系统综述
该系统综述检索PubMed并筛选会议摘要,纳入16项直接比较戈舍瑞林、曲普瑞林和亮丙瑞林的试验。研究显示这些GnRH激动剂在降低睾酮和PSA方面无重大差异,但在睾酮控制、注射部位不良事件及患者认知方面可能存在差异,现有证据不足以证明等效性。
要点
- GnRH激动剂降低睾酮和PSA的效果相似,但证据不足以证明等效。
- 部分研究提示短期或长期睾酮控制、注射部位不良事件率及患者认知存在差异。
- 现有直接比较试验患者数少、制剂和终点受限,均未对生存结局充分把握度。
核心结论
- GnRH激动剂提供相似的去势效果,但证据不足以表明这些药物等效。
研究设计与样本
- 系统综述,2017年6月在PubMed由两名评价员独立检索,无时间限制,并筛选相关会议摘要。
- 共纳入16项直接比较试验:12项报告疗效结局,4项报告安全性/耐受性,5项报告给药便利性/使用者认知。
主要发现
- 报告疗效终点的研究未显示这些GnRH激动剂在降低睾酮或前列腺特异性抗原水平方面存在重大差异。
- 部分研究提示短期或长期睾酮控制、注射部位不良事件发生率以及患者/医护人员认知可能存在差异。
临床怎么用
- 临床选择GnRH激动剂时需考虑现有证据不能证明等效,应结合患者具体情况和耐受性进行个体化决策。
局限性
- 直接比较试验数量少,患者数量、评估的制剂和终点均受限。
- 没有一项研究对生存结局指标有足够的把握度。
- 现有证据无法得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To review direct comparative studies of the gonadotrophin-releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'goserelin' and 'leuprorelin', without time restriction. Duplicates were deleted. Relevant conference abstracts were also screened. A total of 16 direct comparative trials were identified: 12 reported on efficacy outcomes, four on safety/tolerability, and five on the convenience of administration/user perceptions. These studies are restricted in terms of patient numbers, formulations assessed, and endpoints measured; none were adequately powered for survival outcome measures. Studies reporting on efficacy endpoints did not show major differences in the ability of these GnRH agonists to reduce levels of testosterone or prostate-specific antigen. Some studies suggest differences in short- or long-term testosterone control, the rate of injection site adverse events, and patient/healthcare professional perceptions, but definitive conclusions cannot be drawn from the existing evidence. Few direct comparative trials of GnRH agonists have been conducted. Whilst GnRH agonists provide a similar castration effect, there is not enough evidence to show that GnRH agonists are equivalent.
引用
- Bolton EM, Lynch T. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. BJU Int. 2018. PMID: 29438592. doi:10.1111/bju.14168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。